A non-inferiority randomized controlled clinical trial comparing Unani formulations and PUVAsol in non-segmental vitiligo.
Baraṣ
Habb-i Baras
Habb-i Hindi
PUVAsol
VASI
non-segmental vitiligo
Journal
Journal of complementary & integrative medicine
ISSN: 1553-3840
Titre abrégé: J Complement Integr Med
Pays: Germany
ID NLM: 101313855
Informations de publication
Date de publication:
01 Mar 2023
01 Mar 2023
Historique:
received:
25
02
2021
accepted:
09
06
2021
pubmed:
24
6
2021
medline:
24
6
2021
entrez:
23
6
2021
Statut:
epublish
Résumé
Greco-Arab medicine is an ancient system of medicine with greater treasure on therapeutics of vitiligo. The trial Unani formulations have not been scientifically explored for their safety and efficacy, but have been repeatedly prescribed by the great Unani physicians in the management of In this randomized, controlled, open-label clinical trial, 82 participants with non-segmental vitiligo aged 18-40 years were block randomized to either receive Unani interventions or control for 16 weeks. Out of 82 participants, 42 were randomized to the Unani group and 40 were randomized to the control group. The primary outcome measure was change in vitiligo area scoring index (VASI), which was assessed on weeks 4, 8, 12 and 16. The secondary outcome measures included the patient's global assessment on VAS and investigator's global assessment based on photographic evaluation at baseline and after the treatment. Safety parameters included hemogram, LFTs, RFTs, CXR, ECG, urine, and stool examinations, which were evaluated at baseline and after the treatment. The per-protocol analysis was done on 30 participants in each group and the response in Unani group was not inferior to those receiving control group. The mean ± SD of vitiligo area scoring index (VASI) decreased from 4.09 ± 2.87 and 5.50 ± 5.73 at baseline to 3.13 ± 2.20 and 4.29 ± 4.95 at the end of the trial in both the Unani and control groups respectively. The study inferred that both the interventions are equally effective and well-tolerated in patients with non-segmental vitiligo.
Identifiants
pubmed: 34162019
pii: jcim-2021-0057
doi: 10.1515/jcim-2021-0057
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
250-257Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Christopher, G, Barker, J, Bleiker, T, Robert, C, Creamer, D. Acquired Pigmentary Disorders. Rook’s Textb. Dermatology , 9th ed., vol. 3. Wiley-Blackwell; 2016:88.34–6 pp.
Ezzedine, K, Sheth, V, Rodrigues, M, Eleftheriadou, V, Harris, JE, Hamzavi, IH, et al.. Vitiligo is not a cosmetic disease. J Am Acad Dermatol 2015;73:883–5. https://doi.org/10.1016/j.jaad.2015.07.039 .
doi: 10.1016/j.jaad.2015.07.039
Porter, J, Beuf, A, Nordlund, JJ, Lerner, AB. Personal responses of patients to vitiligo: the importance of the patient-physician interaction. Arch Dermatol 1978;114:1384–5. https://doi.org/10.1001/archderm.1978.01640210075025 .
doi: 10.1001/archderm.1978.01640210075025
Krüger, C, Schallreuter, KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012;51:1206–12. https://doi.org/10.1111/j.1365-4632.2011.05377.x .
doi: 10.1111/j.1365-4632.2011.05377.x
Yaghoobi, R, Omidian, M, Bagherani, N. Vitiligo: a review of the published work. J Dermatol 2011;38:419–31. https://doi.org/10.1111/j.1346-8138.2010.01139.x .
doi: 10.1111/j.1346-8138.2010.01139.x
Taïeb, A, Picardo, M. Clinical practice. Vitiligo. N Engl J Med 2009;360:160–9. https://doi.org/10.1056/nejmcp0804388 .
doi: 10.1056/nejmcp0804388
Hann, SK, Lee, HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996;35:671–4. https://doi.org/10.1016/s0190-9622(96)90718-5 .
doi: 10.1016/s0190-9622(96)90718-5
Schallreuter, KU, Bahadoran, P, Picardo, M, Slominski, A, Elassiuty, YE, Kemp, EH, et al.. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008;17:139–40. https://doi.org/10.1111/j.1600-0625.2007.00666_1.x .
doi: 10.1111/j.1600-0625.2007.00666_1.x
Spritz, RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigm Cell Res 2007;20:271–8. https://doi.org/10.1111/j.1600-0749.2007.00384.x .
doi: 10.1111/j.1600-0749.2007.00384.x
Rāzī ABM ibn, Z. Disease of the Skin (Ringworm, Leukoderma, Leprosy etc.) and Dyes of Hair and Hands. Kitāb al-Ḥāwī f’il Ṭibb (Arabic version), vol. 23, Part-II , 1st ed., Hyderabad: Dairatul Marif, Osmania University (Osmania Oriental Publication Bureau); 1970:88–119 pp.
Ṭabrī, A, Ḥasan A bin, M. Al-Mu‘ālajat al-Buqrāṭiya , vol. II. New Delhi: Central Council For Research in Unani Medicine; 1997:199–200 pp.
Ibn Sīnā, A. Al-Qānūn fi’l Ṭibb , 1st ed. Lahore: Shaikh Muhammad Basheer and Sons, Urdu Bazar; n.d.:351–3 pp.
Jurjāni, AH. Dhakhīra Khawārizm Shāhī . New Delhi: Idara Kitab-us-Shifa, 2075, Kucha Chelan, Darya Ganj; 2010:18–21 pp.
Ṭibb-i Akbar, AA. Deoband . Jama Masjid, Deoband: Faisal Publications; n.d.:731–2 pp.
Gāzrūnī S al-D. Al-Sadīdī (Arabic) . Lucknow: Maṭba Munshi Nawal Kishor . Lucknow, India, U.P.; n.d.:61–2 pp.
Standard Unani Medical Terminology . New Delhi: Central Council For Research in Unani Medicine; 2012:32 p.
Rāzī ABM ibn, Z. Kitāb al-Manṣūrī (Urdu Translation) . New Delhi: Central Council For Research in Unani Medicine; 1991.
Whitton, ME, Pinart, M, Batchelor, J, Leonardi-Bee, J, González, U, Jiyad, Z, et al.. Interventions for vitiligo. Cochrane Database Syst Rev 2015;2015. https://doi.org/10.1002/14651858.CD003263.pub5 .
doi: 10.1002/14651858.CD003263.pub5
Shenoi, S, Prabhu, S. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol 2014;80:497–504. https://doi.org/10.4103/0378-6323.144143 .
doi: 10.4103/0378-6323.144143
Allam, M, Riad, H. Concise review of recent studies in vitiligo. Qatar Med J 2013;2013:1–19. https://doi.org/10.5339/qmj.2013.10 .
doi: 10.5339/qmj.2013.10
The Unani Pharmacopoeia of India Part-I , vol. IV. New Delhi: Dept. of AYUSH, Ministry of Health & Family Welfare, Government of India; 2007.
National Formulary of Unani Medicine Part-II , vol. I. New Delhi: Dept. of AYUSH, Ministry of Health & Family Welfare, Government of India; 2007.
Husain, N, Qamaruddin, Kazmi, MH. Clinical studies on the treatment of Baraṣ (vitiligo) in Unani system of medicine—a systematic review. Eur J Biomed Pharmaceut Sci 2018;5:1088–94.
Kabīruddin, H. Makhzan al-Mufradāt (Khwāṣ al-Advia) . New Delhi: Ejaz Publicating House; 2007:107 p.
Hakīm K. Al-Qarābādīn . Tabaʻ Sāni . New Delhi: Central Council For Research in Unani Medicine; 2006:231 p.
Ravishankar, V, Rathod, SP, Saikia, S, Chaudhary, RG, Solanki, RB. A study of comparison of PUVASOL and NBUVB in patients with vitiligo. Pigment Int 2018;5:96.
Naveen, N, Hanumanthappa, H. Clinico-epidemiological study of vitiligo and its correlation with thyroid function. J Evid Based Med Healthc 2015;2:6227–34. https://doi.org/10.18410/jebmh/2015/858 .
doi: 10.18410/jebmh/2015/858
Krupa Shankar, D, Madala, R, Shashikala, K. Clinical patterns of vitiligo and its associated co morbidities: a prospective controlled cross-sectional study in South India. Indian Dermatol Online J 2012;3:114. https://doi.org/10.4103/2229-5178.96705 .
doi: 10.4103/2229-5178.96705
Martis, J, Bhat, R, Nandakishore, B, Shetty, JN. A clinical study of vitiligo. Indian J Dermatol Venereol Leprol 2002;68:92–3.
Lerner, AB, Nordlund, JJ. Vitiligo: what is it? Is it important? JAMA J Am Med Assoc 1978;239:1183–7. https://doi.org/10.1001/jama.1978.03280390079031 .
doi: 10.1001/jama.1978.03280390079031
Sehgal, VN, Srivastava, G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149–56. https://doi.org/10.4103/0378-6323.32708 .
doi: 10.4103/0378-6323.32708
Ali, D, Mannan, A, Misbahuddin, S. Bars aur uskey ilaj mein safoof bars ki ifadiat ka jaiza . Aligarh Muslim University; 2015.
Gopal, KVT, Rama Rao, GR, Kumar, YHK, Appa Rao, MV, Vasudev, P, Srikant . Vitiligo: a part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol 2007;73:162–5. https://doi.org/10.4103/0378-6323.32710 .
doi: 10.4103/0378-6323.32710
Dave, S, Thappa, D, Dsouza, M. Clinical predictors of outcome in vitiligo. Indian J Dermatol Venereol Leprol 2002;68:323–5.
Behl, PN, Kotia, A, Sawal, P. Vitiligo: age-group related trigger factors and morphological variants. Indian J Dermatol Venereol Leprol 1994;60:275–9.
Shajil, E, Agrawal, D, Vagadia, K, Marfatia, Y, Begum, R. Vitiligo: clinical profiles in Vadodara, Gujarat. Indian J Dermatol 2006;51:100–4.
Sultan, T, Ali, SA. Psoralea corylifolia extracts stimulate cholinergic-like psoralen receptors of tadpole-tail melanophores, leading to skin darkening. J Recept Signal Transduct 2011;31:39–44. https://doi.org/10.3109/10799893.2010.508164 .
doi: 10.3109/10799893.2010.508164
Yin, L, Pang, G, Niu, C, Habasi, M, Dou, J, Aisa, HA. A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells. Int J Mol Med 2018;41:3727–35. https://doi.org/10.3892/ijmm.2018.3529 .
doi: 10.3892/ijmm.2018.3529
Kumar, VS, Navaratnam, V. Neem (Azadirachta indica): prehistory to contemporary medicinal uses to humankind. Asian Pac J Trop Biomed 2013;3:505–14. https://doi.org/10.1016/s2221-1691(13)60105-7 .
doi: 10.1016/s2221-1691(13)60105-7
Jadhav, PB. Chemical leucoderma of oral and labial mucosal surfaces from neem [Azadirachta indica]. A case series. Indian Dermatol Online J 2020;11:433–5. https://doi.org/10.4103/idoj.IDOJ_226_19 .
doi: 10.4103/idoj.IDOJ_226_19
Ali, M, Chaudhary, N. Ficus hispida Linn.: a review of its pharmacognostic and ethnomedicinal properties. Pharmacogn Rev 2011;5:96–102. https://doi.org/10.4103/0973-7847.79104 .
doi: 10.4103/0973-7847.79104
Mahboubi, M. Zingiber officinale Rosc. essential oil, a review on its composition and bioactivity. Clin Phytoscience 2019;5:1–12. https://doi.org/10.1186/s40816-018-0097-4 .
doi: 10.1186/s40816-018-0097-4